Sutro Biopharma Inc. (STRO)
Sutro Biopharma Inc. (STRO) Stock Price, Analysis & Data
| Bid | 18.57 |
| Market Cap | 363.96M |
| Revenue (ttm) | 45.7M |
| Net Income (ttm) | -180.64M |
| Beta | 1.51 |
| EPS (ttm) | -17.37 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.27 |
| P/B (ttm) | -5.44 |
| P/S (ttm) | 7.96 |
| Earnings Date | n/a |
| Ask | 31.7 |
| Volume | 520,408 |
| Avg. Volume (20D) | 368,780 |
| Open | 21.99 |
| Previous Close | 22.28 |
| Day's Range | 20.78 - 22.99 |
| 52-Week Range | 7.15 - 43.85 |
| Analyst | Strong Buy |
| Price Target | 50 (126.86%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About STRO
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head...
Financial Performance
In 2025, Sutro Biopharma's revenue was 102.48M, an increase of 65.18% compared to the previous year's 62.04M. Earnings were -191.09M, a decrease of -15.99%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for STRO stock is "Strong Buy". The 12-month stock price forecast is 50, which is upside of 126.86% from the latest price.
Stock Forecasts
